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ABSTRACT
Introduction: Physical activity is a cornerstone in type
2 diabetes (T2D) rehabilitation. Effective long-term and
low-cost strategies to keep these patients’ physically
active are needed. However, maintaining physical
activity behaviour is difficult once formalised
interventions end. Structured exercise training
supported by mobile technology and remote feedback
is potentially an effective strategy. The objective of the
trial is to investigate whether mobile health support
using the InterWalk application for smartphones is
effective in increasing physical activity levels in persons
with T2D over time compared with standard care. We
investigate whether Interval Walking Training using the
InterWalk application is superior to Danish
municipality-based rehabilitation in increasing
moderate-and-vigorous physical activity levels in
patients with T2D across 52 weeks. Secondary, we
hypothesise that a motivational programme added
from end of intervention to 52 weeks further
increases level of physical activity in everyday life in
patients with T2D.
Methods and analysis: The trial is a parallel-
group, open-labelled, randomised controlled trial
with long-term follow-up at 52 week including
patients with T2D. The primary outcome is change
in moderate-and-vigorous physical activity. The key
secondary outcome includes motivation for physical
activity behaviour change. Other secondary
outcomes are VO2-peak, strength in the lower
extremities. Exclusion criterion is medical
contraindication to exercise. We include up to 246
patients and randomly allocate them into a control
(standard group) or an experimental group
(8–12 weeks of IWT supported by the smartphone-
based InterWalk application) in a 1:2 fashion. After
intervention, the experimental group is randomly
allocated into two follow-up conditions with
unsupervised IWT with or without motivational
support until 52-week follow-up. The intention-to-
treat principle is applied.
Ethics and dissemination: The local regional
Research Ethics Committee in Denmark (H-1-2014-
074) and the Danish Data Protection Agency ( j.nr.
2014-54-0897) have approved the trial. Positive,
negative or inconclusive results will be disseminated
in scientific journals and conferences.
Trial registration number: NCT02341690.
Strengths and limitations of this study
▪ The trial is the largest of its kind, and meets the
criteria for high-quality randomised controlled
trials with central randomisation and use of valid
and reliable measures.
▪ The trial has a long-term follow-up period of
52 weeks from baseline.
▪ The trial has high external validity with relevance
for the clinical setting as it is performed within
clinical practice and includes a limited use of
inclusion/exclusion criteria.
▪ The trial has several collaborators in the set-up,
which may cause variation in the testing
procedures.
▪ Lack of clinical end points, for example, depres-
sion and mental health.
▪ The length of the intervention periods varies
between the three collaborating municipalities
may influence the results of the trial.
▪ There may be a risk of contamination in the
control group as the InterWalk application can be
downloaded in App Store.
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INTRODUCTION
Physical activity (PA) is a cornerstone in the clinical care
of patients with type 2 diabetes (T2D).1 PA has beneﬁ-
cial effect on glycaemic control and other key metabolic
risk factors,2 3 as well as improvements in quality of
life.4 5 Furthermore, supervised long-term PA interven-
tions have proven effective in improving glycaemic
control.2 6 However, experimental evidence does not
support the efﬁciency of advice about PA alone.3 As the
number of patients with T2D is estimated to rise to 500
million by 2030 worldwide,7 8 the implementation of
structured, long-term and supervised exercise regimes
constitutes a large societal challenge and is not feasible.
Thus, novel strategies to increase PA among patients
with T2D are needed.
Smartphones have been used as a tool to register exer-
cise, diet, weight and plasma glucose levels, but the evi-
dence for using a smartphone as an exercise device and
a self-management tool in the diabetes care is lacking.9
However, emerging evidence suggests that eHealth solu-
tions using information and communication technolo-
gies10 can educate and engage patients with T2D in
long-term self-management.11–13 Owing to the large
ingress and ownership of smartphones, a smartphone-
supported approach could prove feasible in increasing
PA among patients with T2D and accommodate the
increasing prevalence of T2D.
Efﬁciency of Interval Walking Training (IWT) in
patients with T2D has been established.14 In the study
by Karstoft et al, IWT was administered and monitored
using a small exercise computer ( JD-mate). IWT
induced signiﬁcant improvements in physical ﬁtness
level, body composition and glycaemic control and in
adherence of >85% over a 16-weeks period.14 The poten-
tial beneﬁts of implementing eHealth solutions in T2D
management and the apparent health beneﬁts of and
adherence to IWT gave rise to the development of the
InterWalk application (InterWalk app) to deliver IWT.15
There is a lack of knowledge about the integration
of PA in the everyday life of the patient following
rehabilitation interventions.16 It is, however, known that
successful behavioural change depends on an ongoing
maintenance of individual motivation regarding
the behaviour and behavioural change itself.17
Furthermore, time since onset of diagnosis, unhealthy
behaviour and own beliefs about the cause of the
problem, together with the number of previous
attempts to change and support from partners, peers
and health professionals are of relevance.17 This under-
lines the need for new interventions with a direct focus
on motivational support and self-control regarding sus-
taining a newly acquired behavioural change with PA.
To better target and structure manageable interven-
tions related to patients with T2D, understanding
patients’ individual priorities and values is crucial. In
this regard, knowledge of individual motivation and
self-efﬁcacy to initiate behavioural changes becomes
essential to understand.17
This paper presents a detailed protocol for the
InterWalk randomised controlled trial and is described
in accordance with the SPIRIT guidelines (Standard
Protocol Items: Recommendations for Interventional
Trials).18 Results from the trial will follow CONSORT
guidelines (CONsolidated Standards Of Reporting
Trials) for non-pharmacological interventions.19
Trial objective and hypothesis
The objective of the trial is to investigate whether
mobile support using the InterWalk application for
smartphones is effective in increasing PA levels in
persons with T2D over time compared with a standard
care rehabilitation programme.
We investigate the effectiveness of the implementation
of IWT using the InterWalk application in the Danish
municipality-based rehabilitation programme and study
whether the IWT is superior to standard care in in-
creasing moderate-to-vigorous PA 52 after weeks.
Furthermore, we expect that a motivational support pro-
gramme added from end of the intervention to 52 weeks
will increase the PA level in patients with T2D and help
maintain a physically active everyday life long term.
METHODS AND ANALYSIS
Trial design and setting
The trial is a 52-week parallel-arm, open-labelled, rando-
mised controlled trial. The participants are randomly
allocated into two groups, (1) standard care or (2) experi-
mental group with moderate-and-vigorous PA level, doing
interval walking facilitated by the InterWalk app. After an
8–12-week intervention period, patients in the experi-
mental group are allocated to do interval walking using
the InterWalk app with or without motivational support
provided by the health professionals (see ﬁgure 1).
The intervention is conducted at the health promo-
tion centres in Danish municipalities and hospitals that
consecutively are included as cooperation partners. The
municipality of Copenhagen is the ﬁrst collaborator in
the trial. Patients were referred to rehabilitation by their
general practitioner (GP). Trained health professionals
(physical therapists, nurses and staff with a master’s
degree) working at the health promotion centres recruit
the patients, deliver the interventions and conduct all
testing. The overall organisation of healthcare in
Denmark is fully tax-ﬁnanced with universal access to
healthcare services. The Danish model is described in
detail elsewhere20 21 and chronic disease care (including
T2D) management is in Denmark based in the Chronic
Care Model.22
Brieﬂy, GPs refer patients diagnosed with T2D to
rehabilitation either at an outpatient clinic within a
municipality or at the hospital level in Denmark. The
setting depends on stage of the disease, presence of
complications and comorbidities, for example, severe
heart conditions, depression or mental illness. The
municipality-based rehabilitation primarily includes non-
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complicated patients (∼80% of all patients).20 If compli-
cations or comorbidities are present, patients are
referred to treatment at a specialised clinic at a hospital.
Patients with a non-complicated course of disease
receive rehabilitation consisting of: (1) disease-speciﬁc
patient education, (2) diet counselling, (3) smoking ces-
sation and (4) exercise. The composition of the individ-
ual rehabilitation programme depends, however, on
disease progression and on the rehabilitation offered in
the municipality-based programme or at the hospital.
The general focus is patient empowerment, disease-
related self-care and prevention of a decay of the func-
tional capacity of patients with T2D.
The InterWalk application is approved by the Danish
Data Protection Agency (2008-58-0035). The trial has been
registered at http://www.clinicaltrials.org (NCT02341690)
on 9 January 2015. Amendments to the protocol will be
approved by the Scientiﬁc Ethical Committee at the
Capital Region of Denmark. Amendments will be reported
to http://www.clinicaltrials.org. The trial is conducted in
accordance with the Helsinki Declaration.
Participants
Eligibility
All non-complicated patients diagnosed with T2D (out-
patients), referred to a health promotion centre or hos-
pital in the participating municipalities by their GP, are
eligible if >18 years of age. A ﬂow chart of participants is
presented in ﬁgure 2.
The exclusion criteria are medical contraindications
to exercise, for example, chronic complications in the
locomotive apparatus, painful osteoarthritis or heart
conditions.23 Information is collected through medical
records and at a screening interview with a health pro-
fessional at the health promotion centre. Furthermore,
patients are excluded if they do not want to be physically
active in the rehabilitation setting or are already partici-
pating in other intervention studies at a health promo-
tion centre. The patients have to be able to talk, read
and understand the Danish language (for overview over
inclusion and exclusion criterion, see box 1).
If eligible, health professionals give oral and forma-
lised written information with 2 days to consider partici-
pation in the trial. Written informed consent is obtained
before any additional trial procedures. Enrolment was
initiated in January 2015 and recruitment is terminated
on 15 December 2016. Last visit of last patient is
expected in December 2017.
Interventions
The trial is developed in collaboration with the health
professionals from the municipality of Copenhagen in
Denmark. The interventions are designed to reﬂect the
clinical rehabilitation settings in Denmark to increase
the likelihood of implementation of the programme fol-
lowing this trial, if proven superior. Health professionals
from the municipalities already providing the rehabilita-
tion deliver all interventions in the control and
Figure 1 Timeline and overview of interventions in the InterWalk trial. Phase I shows baseline-test, randomisation, intervention
and test after intervention. Phase II shows the reallocation of patients in the experimental group who do Interval Walking Training
(IWT with the InterWalk app to either IWT with or without motivational support form a health professional). All patients are tested
at baseline, after intervention and again at follow-up at 52 weeks.
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experimental groups during the trial period. The investi-
gators (LSV, CB and HL) led four workshops (16 hours
in total) with the health professionals during year 2014,
in which the interventions of the study and work rou-
tines were discussed in detail. Furthermore, all partici-
pating health professionals underwent a thorough
education programme (15 hours in total) involving all
procedures and manuals in the trial. This was carried
out to ensure standardisation of all procedures through-
out the trial. In addition, workshops were held from the
start of the trial ( January 2014) and hereafter every
second month. This is carried out to secure that the
health professionals follow all procedures and prepared
manuals throughout the trial. The applicability of the
Figure 2 Flow chart, The InterWalk-RCT Trial. RCT, randomised controlled trial.
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trial results is increased here, as the interventions are
already part of the rehabilitation programme offered to
patients with T2D in the municipalities.
The interventions in the trial consist of two phases
(ﬁgure 1). In phase I (8–12 weeks), patients are rando-
mised to either a standard care group (control interven-
tion) or an experimental group doing IWT using the
InterWalk app. The present trial uses the standard care
programme as control intervention and is conducted
directly in the clinical setting. All patients receive super-
vision across phase I. In phase II (40–44 weeks), patients
in the standard care group have no follow-up until
52 weeks postbaseline. Patients in the experimental
intervention group are in phase II randomly allocated to
either IWT with or without motivational support (see
section Experimental intervention—IWT with the
InterWalk application). Additional rehabilitation care
(cointerventions) with disease-speciﬁc patient education,
diet counselling and smoking cessation is offered to all
patients across the intervention groups. The interven-
tions are summarised in table 1.
Experimental intervention—IWT with the InterWalk
application (phase I and II)
Patients allocated to the experimental intervention do
interval walking after baseline test provided by health
professionals (phase I). IWT is provided by health pro-
fessionals to smaller groups of 3–12 patients. After the
intervention period in phase II, patients are allocated to
either receive IWT without motivational support during
follow-up (IWTgroup) or IWT with motivational support
during follow-up (IWTsupport-group) (ﬁgure 1).
Trained health professionals conduct the IWT sessions
(see below) and the motivational support in phase II.
Table 1 gives an example of a typical week with interval
walking in the experimental intervention group.
IWT using the InterWalk application
IWT is performed using the InterWalk app, which works
as a personal trainer as well as a monitoring unit allow-
ing researchers to continuously and automatically
monitor and store the PA level in a central database
(ﬁgure 3).15
IWT is personalised through a standardised 8 minute
walking test, performed with the app before engaging in
IWT.24 The InterWalk app guides the user in IWT with
repeated cycles of 3 min fast and 3 min slow walking.
During IWT, the InterWalk app provides the patient with
continuous feedback on the walking speed. The patients
are able to track exercise history and receive historic
feedback on the quality of the IWT session using the
app. The feedback system employs the on-board acceler-
ometer of the phone and GPS system to assess intensity
and geographical location. Information on training
intensity, total number of steps per day, IWT-data and
data from the standardised walking test is stored in the
smartphone or iPod and automatically transmitted to
the central database at the Danish Strategic Research
Centre for Type 2 Diabetes (DD2) when connected to
Wi-Fi or mobile data network.15
Experimental intervention, phase I
The patient receives a thorough introduction to the
InterWalk app with follow-up instructions. The introduc-
tion consists of information and test of the app and the
patient can ask clarifying questions if needed. A detailed
manual regarding the InterWalk app is extradited to each
patient. The health professional provides technical guid-
ance and helps the patient to structure an everyday life
with IWT during phase I. Patients are encouraged
to perform IWT using the InterWalk app (see section:
InterWalk Walking Training using the InterWalk
Application) as a minimum three times per week,
30–60 min per session, with two of the sessions taking
place at the health promotion centre and the third is con-
ducted in the patient’s everyday life environment. The
aim is that all patients are capable of continuing IWT
using the InterWalk app at the end of phase I (table 2).
Experimental intervention, phase II
In phase II, patients in the experimental intervention
group are randomly allocated into two follow-up condi-
tions: with unsupervised IWTwithout support (IWTgroup)
or with motivational support (IWTsupport-group) follow-
ing the intervention period until 52-week follow-up (see
ﬁgure 1).
Interval Walking Group without support (IWTgroup)
All patients in the Interval Walking Group (IWTgroup)
are encouraged to continue to perform IWT with the
InterWalk app three times a week, 30–60 min per
session. The patients are not provided with any follow-up
or support from health professionals from the end of
the intervention period until follow-up at 52 weeks.
However, patients are allowed to contact the health pro-
fessionals at the health promotion centre at any time if
necessary.
Interval Walking Group with support (IWTsupport-group)
Patients in the Interval Walking Group with support
(IWTsupport-group) are also encouraged to do IWT
with the InterWalk app three times per week. All
patients in the IWTsupport-group receive additional
Box 1 Eligibility criteria
Inclusion criteria
▪ Diagnosed with type 2 diabetes
▪ Referred by general practitioner to a health promoting centre in
participating municipality or hospital
Exclusion criteria
▪ <18 years of age
▪ Medical contraindications to exercise
▪ Already participating in other exercise trials
▪ Does not talk and read Danish
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Table 1 Interventions in the trial during phase I and II
Phase I Standard care (control intervention)
Group-based training at the health promotion centre
(control intervention)
(1/3)
▸ Group-based sessions with 4–12 patients.
▸ Two sessions per week at the health promotion centre.
▸ Warm-up exercises.
▸ Cardiorespiratory exercises.
▸ Resistance training.
▸ Cool-down period.
Experimental intervention
Interval Walking Training
(IWT) (2/3)
▸ Group-based Interval Walking Training (IWT) using the InterWalk app.
▸ Introduction to the InterWalk app.
▸ Follow-up instructions and guidance.
▸ IWT using the InterWalk (IW) app.
▸ Three times per week, 60 min per session—twice a week at a health promotion centre in a
group and one time alone in everyday life.
▸ End of phase I: preparation to continue IWT with IW app in the end of the intervention
period, through a transition programme.
PHASE II Standard care (control intervention)
Group-based training at the health promotion centre
(control intervention) (1/3)
▸ No intervention at the health promotion centre.
▸ Follow-up at 52 week.
Experimental intervention
IWTgroup (1/3) ▸ No intervention at the health promotion centre.
▸ Follow-up at 52 weeks.
IWTsupport-group (1/3)Motivational support
1. Individual motivational interviews with individual
goal setting (semi-structured).
2. Short message service (SMS).One weekly SMS
and one SMS every forth week.
3. Interval Walking Ambassadors.
▸ Four semistructured individual motivational interviews are scheduled in phase II: week 16,
20, 28, 40.
▸ Each interview is scheduled to last 30 min.
▸ Individual goal setting related to everyday life following the SMART—principle.
▸ The aim of goal setting is to help the patient reflect on their physical activity habits.
▸ Weekly SMS.
▸ The reply indicates amount of IWT during the past week (none, 1–2 or 3 or more).
▸ If no reply for 2 consecutive weeks, or if the reply indicates none walking, then the patient is
contacted by phone by a health professional.
▸ SMS every fourth week.
▸ Encourages the patient to make a new walking test using the InterWalk app.
▸ Educated patients with T2D do interval walking in local community near the health promotion
centres.
▸ One session per week.
Cointerventions
(across phase I
and II)
Additional rehabilitation care (cointerventions) with specific focus areas
Patient education Disease-related education regarding living with type 2 diabetes, empowerment and
self-management and medication handled by either medical doctor, a nurse, physical therapist
or dietitian and another patient with type 2 diabetes—group based or individually handled.
Diet counselling Diabetes-specific diet counselling—group based or individually handled by a dietitian.
Smoking cessation Smoking cessation courses is handled by smoking cessation counsellors
The course lasts 10-12 hours and can be either individually or group based.
SMART, specific, measurable, achievable, relevant and timely; T2D, type 2 diabetes.
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motivational support by the health professionals at the
promotion centre (see below for information regarding
the motivational support).
Motivational support (phase II)
The motivational support is summarised in box 2. The
motivational intervention consists of four motivational
interviews with individual goal setting and weekly short
message service via the mobile phone (a SMS-track),
(see ﬁgures 4 and 5). Furthermore, patients have
the opportunity to participate in IWT at predeﬁned
timeslots with an Interval Walking Ambassador in
the local community near the health promotion centre
(see ﬁgure 1).
Motivational interview and goal setting
All health professionals from the municipalities are well
educated in conducting the motivational interview with
patients. All health professionals working in a health
promotion centre in Denmark are obligated to partici-
pate in formalised motivational interviewing courses
conducted by educators with psychological background.
The motivational interview is a semistructured interview
used to structure the communication between the
patient and the health professional. The interview works
as a partnership where focused and detailed questions
reveal and visualise the patients motivation and barriers
towards behaviour change and acknowledgement of
patient autonomy.26 Four motivational interviews are
scheduled for each patient in the IWT support-group.
See box 2 for more detail. The motivational interview
seek to help the patients reﬂect on their physically active
habits and to set individual motivating goals related to
everyday life.27 The health professional secures all notes
and reﬂections from the interview in the InterWalk data-
base. As more than one interview is conducted over the
trial period, ﬁdelity may be ensured when the health
professional uses the patient’s reﬂections from the
former interview to help reﬂect on motivation and bar-
riers towards changes in the next motivational interview.
The goal setting is based on the S.M.A.R.T.—principle
derived from the Goal Setting Theory developed by
Edwin Locke.25 S stands for speciﬁc (eg, what do I want
to accomplish?), M for measurable (eg, speciﬁc and
measurable), A for achievable (realistic), R for relevant
(individual goals) and T for timely (not too big to
achieve in a short period).28
Short message service (henceforth referred to as text
message)
Enables inexpensive and possibly effective interaction
between patients and health professionals at any time or
place (Kongstad et al Effectiveness of remote feedback
on PA in patients with T2D: a systematic review and
meta-analysis of randomised controlled trials. 2016 (sub-
mitted)).29 Communication as well as feedback is
believed to enhance motivation through feelings of com-
petence and relatedness,30 which may positively affect
adherence to treatment. Text messages have shown posi-
tive effect on various health outcomes including dia-
betes self-management when used in behaviour change
interventions. Further, a higher effectiveness and lower
attrition rate has been observed when customised and
tailored messages is used.29 In the present study, the
patient receives two types of text messages during phase
II (see ﬁgures 4 and 5). The ﬁrst type is a weekly and
interactive text message consisting of questions regard-
ing the amount of IWT performed during the past week
(see ﬁgure 4). The patients are required to give feed-
back by returning a text message with one of the three
response options provided. If the patient does not reply
for two consecutive weeks, or if the patient answers that
she/he has not been walking, a personal phone call to
the patient is conducted from a health professional
Figure 3 The InterWalk front page (A), protocol for the fitness test in the application (B), the start page for interval walking
showing smileys as direct feedback to the user (C) (translated from Danish).16
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Table 2 Example of experimental intervention for one week in phase I
Weekday Intervention at the health promotion centre
Independent training in
own environment Notes to health professionals
Monday Duration: 90 min
1. Warm-up: short walk in a group to the walking point (either a park or
an area near the health promotion centre).
2. Interval Walking Training: every patient does Interval Walking
Training with the InterWalk app for a minimum of 30 min. Every
patient does the Interval Walking Training by themselves so that the
app instructions during the session can be followed. The health
professionals guide and facilitate the individual patient if necessary.
After the Interval Walking Training everyone goes back to the health
promotion centre.
3. Group conversation at the health promotion centre after doing
interval walking with all participating patients. Different focus areas
are discussed in the group. Everyone sits on a chair and the health
professional participates as a facilitators in the group conversation
(examples of focus areas: weather conditions, motivation for
exercise, social needs when waking, motivation for a physically
active everyday life).
Remember to encourage and guide every patient to do Interval
Walking Training three times a week either by themselves or
together with other patients.
Make sure that everyone is active during the walking sessions.
If a patient needs to do a new walking test then it is the health
professional who should help during the intervention period.
Every patient needs a new test every fourth week.
Tuesday Rest day
Wednesday Duration: 90 min
1. Warm-up: short walk in a group to the walking point (either a park or
an area near the health promotion centre).
2. Interval Walking Training: every patient does Interval Walking
Training with the InterWalk app for a minimum of 30 min. Every
patient does the Interval Walking Training by themselves so that the
app instructions during the session can be followed. The health
professionals guide and facilitate individual patient if necessary.
After the Interval Walking Training everyone goes back to the health
promotion centre.
3. Group conversation at the health promotion centre after doing
interval walking with all participating patients. Different focus areas
are discussed in the group. Everyone sits on a chair and the health
professional participates as a facilitators in the group conversation
(examples of focus areas: weather conditions, motivation for
exercise, social needs when waking, motivation for a physically
active everyday life).
Thursday Rest day
Friday Rest day
Saturday Interval walking using the
InterWalk application for 30–
60 min.
Can be carried out alone or
together with other patients.
Sunday Rest day
Patients allocated to the experimental intervention do interval walking twice a week, 30–60 min per session during phase I at the health promotion centre in small groups of 3–12 patients. A third
session is conducted in the patient’s everyday life environment.
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from the local health promotion centre. The aim of the
call is to encourage and help the patient to plan IWT to
ﬁt the individual life of the patient. The second type of
text message is sent every fourth week, encouraging the
patients to perform the walking test using the InterWalk
app without a requirement of feedback (see ﬁgure 5).
Interval Walking Ambassadors
Using peers to educate other patients with T2D has
shown effective in providing ongoing support over a
longer period.31 32 In this study, volunteer patients with
T2D are recruited through the Danish Diabetes
Association, where a consultant contacts possible patients
via email. The Interval Walking Ambassadors do IWT
locally in phase II with patients from the IWTsupport
group. The Interval Walking Ambassadors receive a 2-day
training programme in the participating municipality by
researchers from the InterWalk research group. At any
time during phase II, patients can attend IWT at prede-
ﬁned timeslots with an Interval Walking Ambassador (see
table 1).
Adherence to interventions
To prevent patients from dropping out during phase I of
the trial, patients are contacted by phone by a trained
health professional if they fail to appear at the planned
training sessions. Up to ﬁve attempts are made to
contact the patient. In phase II, only patients allocated
to the IWTsupport-group are monitored by SMS-track
and supervised during the phase until week 52. Patients
Figure 4 Short message service (SMS), send every Sunday to patients in the IWTsupport-group. IWT, Interval Walking
Training.
Box 2 Motivational interviews with individual goal setting
Phase II, IWTsupport-group
Four semi-structured motivational interviews with individual goal
setting
▸ The interviews aim at helping the patient to reflect
▸ On why and how physical activity can be incorporated in
everyday life
▸ Make informed choices regarding behavioural changes regard-
ing physical activity
▸ Relate to own everyday life
▸ Clarify barriers and facilitators of importance for the individual
▸ Two to three individual goals are set at all interviews
▸ The goals are based on need in the individual everyday life
A short resume with the individual goal setting is written after all
interviews in the database.
The written text is prospectively incorporated in the following
interviews with the patient at the health promotion centre
The interviews are placed in week 16, 20, 28 and 40 postbaseline
test. Goal setting in the interviews is based on the S.M.A.R.T.—
principle derived from the Goal Setting Theory developed by
Edwin Locke.25
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in IWTgroup have no contact with the health profes-
sionals until 52-weeks follow-up (see ﬁgure 1).
Control intervention—standard care
Patients in the control group receive the standard
rehabilitation treatment offered to patients with T2D in
Denmark in a multimodal setting including PA (phase I,
ﬁgure 1). The duration of rehabilitation treatment
differs between participating municipalities, but may not
be shorter than 8 weeks during phase I. At the end of
the standard care rehabilitation programme in the
municipalities, there is no follow-up on the exercise
intervention, which is the normal procedure in Danish
municipalities (phase II, ﬁgure 1).33
The participating municipalities offer group exercise
twice a week at the health promotion centres with 6–15
patients participating depending on the population size
in the participating municipality. The content of the
group exercise period is based on clinical guidelines in
Denmark. A typical session is structured with ﬁrst a short
warm-up session followed by a strength and cardio part
and ﬁnished with a cool-down period with strengthening
(see table 1). Furthermore, it is recommended that the
patients have regularly consultation at the GP every
third month.
Additional rehabilitation care (cointerventions)
All patients receiving rehabilitation at either a health
promotion centre or at the hospital receives an offer of
speciﬁc disease-related patient education, diet counsel-
ling and smoking cessation.33 It is optional whether the
patient participates in one or all additional offers.
Disease-speciﬁc patient education includes a section
focused on behaviour modiﬁcation and self-
management and a speciﬁc part on diseases where the
patients get knowledge regarding sequelae. Diet counsel-
ling regarding nutritional advice when living with T2D is
handled by a dietitian. Smoking cessation is either group
based or in individual process and is handled by
smoking cessation counsellors.
Trial end points and assessments
Previous studies have established that PA inﬂuences gly-
caemic control34 and Karstoft et al14 has shown that PA
with IWT had effect on glycaemic control in patients
with T2D. Moreover, medication and dietary interven-
tions have also proven to improve glycaemic control and
reduce disease-related complications.35–37 In the present
trial, the primary outcome focus is on PA in relation to
everyday life.
Data on the primary and secondary outcomes are
obtained at baseline, postintervention (after 8–12 weeks)
and 52 weeks after enrolment (table 3). To standardise
all measurements between health professionals and par-
ticipating centres, all health professionals use standar-
dised protocols crafted for the trial regarding
procedures and measurements. All data are entered dir-
ectly in an online database (see section: Data manage-
ment and quality control).
Primary outcome
The primary outcome is change in
moderate-to-vigorous-intensity PA from baseline to
52-week follow-up.
Secondary outcomes
The key secondary outcome changes in motivation for
sustaining a behavioural change with PA in everyday life
at 52-week follow-up.
Other secondary outcomes of interest are changes in
patients’ ﬁtness level measured as VO2-peak by the stan-
dardised walking test (part of the InterWalk application)
and health-related quality of life. Strength in the lower
extremities, adherence to intervention and impact of
personality traits on PA in everyday life are also consid-
ered exploratory secondary outcomes. All outcomes are
measured at baseline, after intervention and at 52-week
follow-up (see ﬁgure 2).
Data collection
Level of daily moderate-to-vigorous-intensity PA
It is important to gain knowledge into PA in everyday
life. To determine level of daily moderate-
to-vigorous-intensity PA, a hip-mounted PA monitor
(Axivity AX3, Newcastle, UK) is worn for 7 consecutive
days, at three time periods during the trial period; after
baseline test, after the intervention period and again at
52-weeks follow-up. The monitor is ﬁxed using adhesive
tape (Leukomed T, BSN medical, Germany) on right
side of the lumbar spine. Additionally, a monitor is ﬁxed
on the lateral side of the right thigh (Leukomed T, BSN
medical, Germany) for supporting information about
posture.24 The patients are instructed not to remove the
PA monitor at any time during the three time periods. If
de-attached, the participants are trained in ﬁxing the
Figure 5 Short message service (SMS), Standardised
walking test in the InterWalk application, send every fourth
week to patients in the IWTsupport-group. IWT, Interval
Walking Training.
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Table 3 Summary of data collection and measures
Measurements Description Baseline 8–12 weeks 52 weeks
Demographic*†‡
Age (median) Obtained using self report x – –
Women x – –
Marital status x – –
Diabetes duration x – –
Education level x – –
Height, weight, body mass index Obtained using standard procedures x x x
Medical history*†‡ Obtained using medical records
History of heart disease x x x
Hypertension x x x
Kidney disease x x x
Chronic obstructive pulmonary disease (COPD) Defined by FEV1<70% x x x
Medicine*†
Self-reported use of medication x x x
Register-data use of medicine x x x
Physical fitness*
Moderate-to-vigorous-intensity Accelerometer (Axivity AX3, Newcastle, UK), worn for 7 consecutive days, three
times
x x x
Total physical activity (VO2-peak) InterWalk—Walking test performed using an iPod touch or IPhone x x x
Strength*
Lower extremities Sit-to-Stand x x x
Patient reported outcomes (PROs)*
Behavioural regulation in exercise Obtained using BREQ-2, Behavioural Regulation in Exercise Questionnaire x x x
Physical activity Obtained using R-PAQ, Resent Physical Activity Questionnaire x x x
Health-related quality of life Obtained using SF-12, Short Form—Health-Related Quality of life Questionnaire x x x
Automaticity of behaviour The Self-Report Habit Index x x
Personality traits† Obtained using NEO-FFI, Neuroticism, Extroversion and Openness—Five Factor
Inventory (Personality traits)
x – –
Risk behaviour† Obtained using SES, Sensation Seeking Scale (risk behaviour) x x x
Adherence to interventions*
Attendance registration
Log in the InterWalk app
From baseline to 8–12 weeks
Measured by the electronic log in the InterWalk-app
x
x
x
x
x
x
Registry data assessment*‡
Mortality, cause of death Obtained using medical records – x x
Hospitalisation – x x
Contract with general practitioner – x x
*Article 1: The effectiveness of smartphone delivered Interval Walking Training on moderate-and-vigorous physical activity versus standard care in patients with type 2 diabetes: a parallel group
single-blinded randomised controlled trial.
†Article 2: Baseline characteristics and personality traits in patients with type 2 diabetes: descriptive study of all participants.
‡Article 3: Nay Sayers—characteristics of patients who does not want to be part of a physical activity study related to everyday life; all patients referred to the health promotion centre in the
municipalities participating in the randomised controlled trial.
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monitors correctly and are instructed to note the inci-
dent. If the patients need help in ﬁxing the monitors
correctly, the health professionals at the health promo-
tion centre are educated to help.
PA diary
To validate the PA level during the 7 days with PA moni-
tors, we ask the patient to complete a 7-day diary to
report number of work and sleep hours, bicycling and
strength training sessions at the three time periods on a
daily basis. The PA monitor and the diary are returned
free-of-charge via mail. The patient is contacted by
phone after within 1 week if the PA monitors are not
returned as expected.
Motivation for behaviour change with PA
Changes in motivation for sustaining a behavioural
change with PA in everyday life is measured with the
Behavioural Regulation of Exercise Questionnaire
(BREQ-2) which measures individual motivation for PA.
The questionnaire consists of 19 questions in a 0–4
Likert format (Jensen et al Validation of the Behavioral
Regulation for Exercise Questionnaire in Danish: meas-
uring of motivation for exercise in people living with
diabetes. 2016 (in preparation)). In addition to the
questionnaire, patients are asked to answer four ques-
tions in a 0–4 Likert format, regarding motivation for PA
after being diagnosed with T2D.
Health-Related Quality of Life
The patient’s Health-Related Quality of Life is very
important to maintain after being diagnosed with T2D
(Valentiner, et al Patients with T2D choose quality of life
over health: a focus group investigation. 2016 (submit-
ted)). To gain knowledge into the individual perception
of quality of life on a physical and mental level we use
the Short-Form Health Survey (SF-12). The question-
naire consists of 12 questions and uses a Likert scale of
1–3 for the physical function items; 1–5 for the bodily
pain, social function and general health perceptions
items; 1–6 for the vitality and mental health and a
dichotomous scale of yes/no for the presence of role
function limitations. The higher score, the higher level
of health or functioning.38
Maintenance of behaviour change with PA
Automaticity of behaviour is essential when new habits
become present in the everyday life.39 To measure if the
patient has adopted new habits as a result of the inter-
vention we ask the patient to answer four questions from
The Self-Report Habit Index. The Index uses a 0–4
Likert format and the four questions to be answered
measures automatic activation, frequency of behaviour
and relevance to self-identity related to PA.40
VO2-peak
VO2-peak is measured by a validated and standardised
walking test consisting of ﬁve stages incorporated in the
InterWalk app; (1) 30 s of standing still, (2) 2 min of
slow walking, (3) 2 min of walking at moderate intensity,
(4) 2 min walking at high intensity and (5) 1 min
walking at highest intensity possible. The four paces are
self-selected (see ﬁgures 3 and 4).24 The test is per-
formed with an iPod placed in the pocket at the hip and
the instructions are delivered from the app through ear-
phones. To ensure the right walking intensity in the
intervention period, the patients are asked to perform
the test every fourth week.15
Strength in the lower extremities
The Sit-to-Stand test (30 s) measures the lower body
strength and will be administered using a chair without
arms. The patient is encouraged to complete as many
full stands as possible within a 30 s time limit.41
Adherence to the intervention
Adherence is determined by an evaluation and quantiﬁ-
cation of the electronic log of data from the InterWalk
app to the central database of all uploaded data.
Self-rated PA
The ‘Recent Physical Activity Questionnaire’ (RPAQ)
has nine main questions, which covers four domains of
PA: domestic life, work, recreation and transport. PA is
estimated in METs (metabolic equivalent). In answering
the questions in the questionnaire, the patient will
answer in regards to the last 4 weeks with PA in the
everyday life.42
Personality traits
The NEO-Five Factor Inventory (NEO-FFI)43 consists of
60 questions in a 0–4 Likert format constructed
by selecting two items from each of the six facets
characterising each of the ﬁve personality traits
(Neuroticism, Extraversion, Openness, Agreeableness,
Conscientiousness) assessed by NEO-PI-R. The Sensation
Seeking Scale (SES)44 is a 40 items self-administered
questionnaire consisting of 40 questions designed to test
the tendency towards varied, novel and intense
sensations.
Demographic, social economic and anthropometry measures
Information on height, weight, waist and hip circumfer-
ence is collected before inclusion through an electronic
questionnaire at the ﬁrst formal meeting at the health
promotion centre and after the intervention period and
again at 52-week follow-up. Waist circumference is mea-
sured at the point between the top of the iliac crest and
the bottom of the costae regardless of the placement of
the umbilicus. A Tanita stadiometer is used to measure
height and an electronic weight to measure weight. Data
on self-reported information together with relevant
national registers will be used to obtain information
regarding hospitalisation, comorbidities, medical history,
use of medicine and mortality.
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Height measurement is conducted using a portable
altimeter (Tanita stadiometer). The measurement is
carried out without shoes and is repeated two times with
each measure to nearest 0.1 cm. If the two measures are
dissimilar with >0.5 cm, then the measurement is
repeated. Weight is measured in kilograms using an elec-
tronic weight. The measure is repeated two times with
each measure to nearest 0.1 cm. If the two measures are
dissimilar with >0.5 kg, then the measurement is
repeated a third time. The patient is weighed fully
dressed and 1 kg is subtracted from each measure. Hip
circumference is measured on the skin on the crest of the
hipbone. The patient is asked to place a ﬁnger in the
belly bottom and the measure is carried out with a tape
measure (2 m) placed on the upper side of the patients’
ﬁnger. If the two measures are dissimilar with >0.5 cm,
then the measurement is repeated a third time.
Safety criteria and adverse events
Patients are informed that performing the InterWalk
walking test may cause some degree of breathlessness as
patients are expected to reach 80–85% of VO2-peak
during the walking test. All other measurements are not
associated with any known risk or discomfort. Injuries
linked to the intervention are registered, if informed to
the health professionals at the health promotion
centres, during the trial period. In case of severe adverse
events, the Scientiﬁc Ethical Committee of the Capital
Region of Demark is informed.
Sample size considerations
The minimum difference of interest (MDI) is 10 min
per day. Based on existing experimental evidence, we
expect the SD of the change in moderate-and-vigorous
PA from baseline to 12-month follow-up to be between
1.2 and 2.3 times the effect size.45 46 Therefore, SD twice
the MDI (20 min of moderate-and-vigorous PA) per day
was applied in the sample size calculations. After apply-
ing Bonferroni adjustment due to multiple comparisons
in the three group trial a total of 190 participants are
needed to obtain a statistical power (1-β) of 80% with an
α of 0.017 (two-tailed). Allowing for an attrition rate of
30%, 272 patients (91 in the control group and 181 in
experimental group) are recruited. The setting enables
recruitment until 15 December 2016. The sample size is
truncated at 272 participants or the N reached at the
end of recruitment period—whatever is reached ﬁrst
(see section ‘Participants’).
Randomisation, sequence generation and allocation
concealment
After returning the PA monitors patients are randomised
to either standard care or experimental group after
baseline test (phase I). Allocation to either IWTgroup
or IWTsupport-group on patients allocated to the experi-
mental group is concealed until after the postinterven-
tion test (phase II). A health professional associated
with the trial, telephones the patient and inform about
random allocation after returning the PA monitors to
either IWT-group or IWTsupport-group. The patients
are stratiﬁed by gender to ensure an equal number
across all groups. The allocation sequence is generated
through a standardised computer programme by an
independent researcher (RC). The allocation sequence
is concealed until the trial arms are assigned. A ﬂow of
patients is depicted in ﬁgure 2.
Blinding
The scientiﬁc staff is blinded to patient allocation from
baseline to the 52-week follow-up is completed for all
patients. The health professionals at the promotion
centre are not blinded to allocation to either standard
care or experimental groups.
Statistical methods
All analyses will be conducted according to the
intention-to-treat principle. Continuous end points will
be analysed using repeated measures analysis of covari-
ance in a mixed linear model. Categorical and dichot-
omous end points will be analysed with the use of
logistic regression. The model will include with group,
and sex as ﬁxed effects, with the baseline value as a
covariate.
All patients randomised to one treatment, will be ana-
lysed according to the treatment to which the patient
was allocated, irrespective of whether they received this
or some other treatment, or no treatment at all. The
intention-to-treat (ITT) population will be handled all
patients randomised to the three treatment arms, and
the data set is equal to the ‘all patients randomised set’
(APRS). Missing values due to patients’ absence from
follow-ups or withdrawal from the study are to be
expected in clinical trials. Several approaches are
described for handling missing data in the ITT analysis,
and among them ‘baseline observation carried forward’
(BOCF: ie, a null-responder imputation, where the level
at baseline is also considered the last). A linear mixed
model analysis includes all patients with a baseline
assessment, and includes ﬁxed and random factors.
Thus, repeated linear mixed model method is chosen
for the primary analyses in this trial (ie, no data imput-
ation), whereas the BOCF imputation, as well as the ‘Per
Protocol’ population will be applied for the purpose of
sensitivity analysis. Also, we will explore whether poten-
tially important covariates such as age, sex, disease dur-
ation, degree of overweight (using body mass index),
and smoking status at enrolment/baseline could poten-
tially confound the results from the primary analyses (ie,
an extra prespeciﬁed sensitivity analysis). Exploratory
analyses of the treatment effects will be performed on
some the secondary outcomes.
Data management and quality control
All data are entered in an secure sockets layer (SSL–
secured, online-based database developed by the Danish
Stakeholder Help2Run (CVR: 34801088). The online-
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based database logistically handles the data gathered at
baseline, after intervention in phase I, and during
follow-up (phase II) and after 52 weeks. Data on demog-
raphy, measurements, tests and questionnaires are
entered directly in the database available via a project-
speciﬁc homepage (http://www.runsafe.dk/mtd/login/
admin-signihttps://www.runsafe.dk/mtd/login/admin-
signin). A protected back-end system (https://www.
runsafe.dk/mtd/admin) is used to logistically handle
information on demography, measurements, tests and
questionnaires on each participant in the trial (for infor-
mation on IWT using the InterWalk app see ‘Interval
Walking Training using The InterWalk Application’. The
system was approved in 2014 after an inspection by the
Danish Data Protection Agency. Access to personalised
data from the InterWalk participants is only possible
using a personalised username and password. Only spe-
ciﬁed researchers are allowed to administrate the
back-end system and each researcher and project
member with access to the back end has a unique user-
name and personal password for the back-end system.
All activities, including changing data and downloading
data, in the back-end system are logged in accordance
with the rules and regulations from the Danish Data
Protection Agency. A unique subject identiﬁcation
(ID) number will be subscribed to all patients to
anonymise data. The identiﬁcation key (ID to personal
information) will be encrypted and stored securely and
separately from the unique ID number on a secure
database.
Ethics and dissemination
The InterWalk trial contributes with important knowl-
edge on different treatment approaches in the rehabili-
tation of patients with T2D. PA and exercise have
beneﬁcial effect on patients with T2D when the inter-
ventions are conducted in well-designed efﬁcacy
studies.2 4 6 However, little is known on whether this
effect also is present in effectiveness studies or ‘real-
world setting’ studies. These studies are of great import-
ance and relevance regarding evidence-based medicine
highlighting the importance of the InterWalk trial.
The InterWalk trial has a pragmatic design that allows
for different intervention periods in the participating
municipalities. Furthermore, the interventions are con-
ducted directly in the clinical setting giving a more reli-
able frame of the experienced challenges in a
population with T2D. We believe that the implementa-
tion of the study results will have a smoother implemen-
tation phase, as the health professionals already are
familiar with the preceding’s.
The trial gives valuable insight into the impact of dif-
ferent motivational and supportive tools as well as knowl-
edge about individual motivation and the impact on
sustaining a newly acquired behaviour change regarding
PA in everyday life.
IWT is expected to be a suitable and effective way of
providing moderate-to-vigorous PA for at large group of
patients with T2D. IWT can be carried out at anytime
and anywhere and is thus integrated and tailored to ﬁt
individual everyday life. The overall objective is to
promote lifelong PA for the individual and we believe
that experiences from the present trial can help when
planning future interventions with IWT to patients with
various lifestyle diseases, for example, coronary heart
diseases.
It is a major advantage that the trial is designed as a
randomised controlled trial in a ‘real-world setting’ with
a study population representing patients with T2D
referred to rehabilitation. Furthermore, data and results
are collected consecutively and directly in the clinical
setting in which the interventions are to be used after
the trial. Together with the very limited number of
inclusion and exclusion criteria and a stratiﬁcation of
patients on gender secures external validity of the trial
and thus will add important information to the current
body of evidence on T2D treatment.
All data from eHealth solutions as the InterWalk app
are electronically monitored. The patient is not
dependent on opening hours at the health promotion
centre as the InterWalk is either installed on an
iPhone or an iPod. This gives a unique possibility for
the patient to be physically active whenever it ﬁts in
their everyday life.
We acknowledge that PA only has effect when adher-
ence is high, which is why we ﬁrst compare standard
care with interval walking for a shorter period (phase I)
followed by a reallocation of patients in the experimen-
tal group to either interval walking with or without
motivational support (phase II). All groups have a
52-week follow-up. The trial design enables us to investi-
gate if patients are able to maintain a newly acquired
behaviour change with PA in everyday life with or
without motivational support for a longer period.
All personalised data and measures are stored on a
central online-based database developed to logistically
handle all data collected at baseline and during
follow-up. The back-end system (https://www.runsafe.
dk/mtd/admin/) secures all information from each
patient. The construction of the database with persona-
lised usernames, passwords and speciﬁc permissions to
all health professionals and administering permissions to
scientiﬁc staff in the back end secures all data.
Furthermore, all activities are logged.
All outcomes measures are assessed blinded to alloca-
tion at baseline and the primary outcome is assessed
blinded to intervention in the experimental group after
the intervention period. All measures are conducted by
the health professionals at the health promotion centres
and are blinded for allocation after intervention in the
experimental group with IWT until after return of the
PA monitors by the patient. All statistical analyses are
blinded to researchers, reducing the risk of detection
and interpretation bias.47–49 All secondary outcomes, but
VO2-peak and the Sit-to-Stand Test are self-reported and
by nature likely to be biased. The patients answer
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questionnaires independently of the health professionals
at the health promotion centres.
The secondary outcomes of motivation for PA and
behaviour change are of highly importance as knowl-
edge concerning motivational support and maintenance
of effect (new habits with PA) to the best of our knowl-
edge is lacking in patients with T2D. This knowledge will
help health professionals to better tailor the treatment
and herby potentially achieve a higher adherence to the
programme following the supervised intervention.
The limitations in this trial are similar to those of
other exercise trials where physical testing and
time-of-day and day-to-day variation constitute a chal-
lenge. We have standardised all testing protocols for all
procedures to reduce the variation and run a routine
programme of ongoing calibration and training of the
health professionals.
The trial is conducted in accordance with the Helsinki
Declaration II.50 All eligible patients receive written and
oral informed consent prior to inclusion before any add-
itional trial procedures. Data on all screened patients
are registered to report characteristics of ineligible
patients and written informed consent is also obtained
from these patients. The patients can withdraw from the
trial at all times during the trial period. This has no con-
sequence for any other future treatment. If patients dis-
continue the trial intervention, standard care is offered
for the rest of the intervention period. All results from
the trial, negative, positive or inconclusive results, are
disseminated in international peer-reviewed scientiﬁc
papers and at national and international conferences.
We follow the guidelines from the International
Committee of Medical Journal Editors when authorship
is determined. The results will be reported when all
long-term data become accessible.
Furthermore, all results are shared with the participat-
ing municipalities and participating health professionals
and are used to develop future intervention and imple-
mentation strategies in the Danish municipalities.
Trial status
The inclusion period started in January 2015 and is
scheduled to ﬁnish in December 2017 with a 52-week
follow-up. To ensure enrolment of patients in the trial,
we are open for collaborations with new municipalities
during the trial period. So far, the trial has resulted in
collaboration with rural and urban municipalities in
Denmark. The inclusion rate is carefully monitored
every week by the research team. In November 2016,
216 patients had been enrolled in the trial.
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